Ibrance (U.S. Pharmaceuticals)
Welcome to the PulseAid listing for the Ibrance drug offered from U.S. Pharmaceuticals. This Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | U.S. Pharmaceuticals |
| NON-PROPRIETARY NAME: | PALBOCICLIB |
| SUBSTANCE NAME: | PALBOCICLIB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | CAPSULE |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-02-03 |
| END MARKETING DATE: | 0000-00-00 |
Ibrance HUMAN PRESCRIPTION DRUG Details:
| Item Description | Ibrance from U.S. Pharmaceuticals |
| LABELER NAME: | U.S. Pharmaceuticals |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 125(mg/1) |
| START MARKETING DATE: | 2015-02-03 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 63539-189_f184bcf9-0b24-4a10-8844-7fea0bc67d9a |
| PRODUCT NDC: | 63539-189 |
| APPLICATION NUMBER: | NDA207103 |
Other PALBOCICLIB Pharmaceutical Manufacturers / Labelers:
